Table 3.

Donor-specific HLA antibody (DSA) levels and engraftment in 5 patients treated with haploidentical transplantation. Changes in DSA levels after rituximab/plasma exchange and post-transplantation. Patients with moderate to high DSA levels against HLA A, B or DRB1 in the pre-transplant serum rejected their graft.

PT #	AB type(a)	Initial titer(b)	R/PE(c)	After R/PE / Pre 1st SCT(d)	Engr Y/N(e)	After 1st SCT /Pre 2nd SCT(f)	Engr Y/N(g)	After 2nd SCT(h)
1	A*3201	NT*	N/A	++++	N	++++	Y	−
2	A*0211	+ + +	Y	+ +	N	+ +	N	NT
	B*3913	+ + +		+ +		+ + +
	Cw*0702	+ + +		NT		NT
	DRB1*0404	+		+		+
3	DRB1*0701	+ +	Y	−	Y	N/A	N/A	N/A
4	DRB1*0701	+ +	Y	+ + +	N	−	Y	N/A
	DRB4*0101	+ + +		+ + +		−
	DQB1*0202	+ + +		+ + +		−
5	DRB1*0401	+ +	Y	+/− (borderline)	Y	N/A	N/A	N/A
	DRB4*0103	+ +		+
	DPB1*0401	+ + +		+ + +

^(a)HLA alleles mismatched in the donor for which the patient had DSA at the initial work-up

^(b)Intensity of donor specific anti-HLA antibodies at the initial work-up

^(c)Treatment with rituximab and plasma exchange prior to the first transplant

^(d)Strength of donor specific anti-HLA antibodies before the first transplant (after treatment with rituximab and plasma exchange)

^(e)Engraftment after the first transplant

^(f)Strength of donor specific anti-HLA antibodies after the first transplant and/or before the seconds transplant

^(g)Engraftment after the second transplant

^(h)Strength of donor specific anti-HLA antibodies after the second transplant

Symbols and abbreviations: - < 500; + 500–1,500; + + 1,500–3,000; + + + 3,000–7,000; + + + + >7,000 fluorescence intensity; PT – patient; AB – antibody ; R – rituximab, PE – plasma exchange, SCT – stem cell transplant; Y – yes; N – no; N/A – not applicable; NT – not tested; NT* - not tested, considered positive for the analysis; Engr – engrafted;